Abstract:transforming the tumor microenvironment from an anti-tumorigenic to a pro-tumorigenic state (Sun & Yu, 2015). Recent findings establish the crucial significance of tumor microenvironment and cancer stem cells in the development of drug resistance, which is the primary cause of cancer recurrence and its inability to be cured. The presence of genetic variations across individuals and tumors, together with the ability of cancer to evade conventional treatments, further complicates the management of medication resistance.Despite rapid development in the design of novel chemotherapy drugs, there is still a lack of effective agents targeting the advanced stages of cancer, namely invasion and metastasis.Through this research topic, we intended to illuminate promising lines of inquiry, namely focusing on new approaches recently discovered in the field, including fundamental genetics, genomic engineering, omics techniques, artificial intelligence, and machine learning. Our goal was to uncover the molecular basis of drug resistance in various cancers, so guiding clinicians in designing and developing therapeutic strategies to improve therapeutic drug sensitivity and overcome resistance. Research presented in this topic showcase novel approaches and openly address the limitations of existing therapeutic remedies. Research papers collected for this topic elucidate the key mechanisms underlying cancer drug resistance and explore potential therapeutic strategies to overcome this obstacle.Several mechanisms have been identified that confer drug resistance in cancer cells. These include increased drug efflux, alterations in drug targets, activation of alternative signaling pathways, and enhanced DNA repair mechanisms (Fernández-Lázaro, 2018). Cancer stem cells have emerged as key contributors to the development of drug resistance and tumor relapse. (Bukowski et al., 2020) (Sun & Yu, 2015).The integration of multi-omics technology, computational methodologies, and the creation of tailored medicines presents novel approaches to address the issue of drug resistance. In conclusion, the challenge of multidrug resistance in cancer remains a significant obstacle in achieving effective and durable cancer therapy. Understanding the complex and heterogeneous mechanisms underlying drug resistance is crucial for developing novel therapeutic strategies.Advancements in cancer immunotherapy, the creation of immune checkpoint inhibitors or targeted small molecules, and the repurposing of non-oncology medications have expanded the scope of ongoing pharmaceutical research. The advancement of nanotechnology-based drug delivery systems has provided promising avenues to overcome these resistance mechanisms and improve patient outcomes. In this context, the application of emerging technologies, such as CRISPR-Cas9-based gene editing, may prove valuable in combating multidrug resistance genes and enhancing the efficacy of cancer treatments.

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

Nicotinamide N -methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization

Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy

SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer

The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance

SIRT1 promotes doxorubicin-induced breast cancer drug resistance and tumor angiogenesis via regulating GSH-mediated redox homeostasis

The dual role of sirtuins in cancer: biological functions and implications

The mechanism by which SIRT1 regulates autophagy and EMT in drug-resistant oesophageal cancer cells

The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer

The Double-Edged Sword of SIRT3 in Cancer and Its Therapeutic Applications

SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer

Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy

Drug metabolizing enzymes and their inhibitors' role in cancer resistance

Sirtuin insights: bridging the gap between cellular processes and therapeutic applications

Updates on altered signaling pathways in tumor drug resistance

Editorial: Revisiting the challenges and opportunities in cancer drug resistance

Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer

The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review

Multifaceted Modulation of SIRT1 in Cancer and Inflammation.

Molecular and Cellular Expressions in Breast Cancer Responsible for Drug Resistance